Developed by Ireland-based BrePco Biopharma, Neoatricon is the first paediatric-strength dopamine hydrochloride infusion for treating hypotension in neonates, infants, and children. Shares of Piramal Pharma Ltd ended at ₹221.25, up by ₹2.75, or 1.26%, on the BSE.
